The Potential Roles of Epigallocatechin-3-Gallate in the Treatment of Ovarian Cancer: Current State of Knowledge

References

• NakachiK, MatsuyamaS, MiyakeS, et al. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. BioFactors. 2000;13(1–4):49–54. doi:10.1002/biof.552013010911237198
   PubMed Web of Science ®Google Scholar
• KurahashiN, SasazukiS, IwasakiM, et al. Study group green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol. 2007;167(1):71–77. doi:10.1093/aje/kwm24917906295
   PubMed Web of Science ®Google Scholar
• YangCS, LandauJM, HuangMT, et al. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr. 2001;21(1):381–406. doi:10.1146/annurev.nutr.21.1.38111375442
   PubMed Web of Science ®Google Scholar
• BimonteS, CascellaM, BarbieriA, et al. Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge. Infect Agent Cancer. 2020;15(1):2. doi:10.1186/s13027-020-0270-531938038
   PubMed Web of Science ®Google Scholar
• BimonteS, CascellaM, BarbieriA, et al. Shining a light on the effects of the combination of (-)-Epigallocatechin-3-gallate and tapentadol on the growth of human triple-negative breast cancer cells. In Vivo (Brooklyn). 2019;33(5):1463–1468. doi:10.21873/invivo.11625
   PubMed Web of Science ®Google Scholar
• BimonteS, AlbinoV, PiccirilloM, et al. Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives. Drug Des Devel Ther. 2019;13:611–621. doi:10.2147/DDDT.S180079
   PubMed Web of Science ®Google Scholar
• BimonteS, CascellaM, LeongitoM, et al. An overview of pre-clinical studies on the effects of (-)-epigallocatechin-3-gallate, a catechin found in green tea, in treatment of pancreatic cancer. Recenti Prog Med. 2017;108(6):282–287. doi:10.1701/2715.2771528631776
   PubMedGoogle Scholar
• BimonteS, CascellaM, LeongitoM, et al. An overview of pre-clinical studies on the effects of (-)-epigallocatechin-3-gallate, a catechin found in green tea, in treatment of pancreatic cancer. Recenti Prog Med. 2017;108(6):282–287. doi:10.1701/2715.2771528631776
   PubMedGoogle Scholar
• NiedzwieckiA, RoomiMW, KalinovskyT, RathM. Anticancer efficacy of polyphenols and their combinations. Nutrients. 2016;8(9):552. doi:10.3390/nu8090552
   PubMed Web of Science ®Google Scholar
• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• LengyelE. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–1064. doi:10.2353/ajpath.2010.10010520651229
   PubMed Web of Science ®Google Scholar
• BoussiosS, KarihtalaP, MoschettaM, et al. Combined strategies With poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review. Diagnostics (Basel, Switzerland). 2019;9(3):87. doi:10.3390/diagnostics9030087
   PubMedGoogle Scholar
• HuSW, BaeSM, KimYW, et al. Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines. Gynecol Oncol. 2004;94(3):760–768.15350370
   PubMed Web of Science ®Google Scholar
• KimYW, BaeSM, LeeJM, et al. Activity of green tea polyphenol epigallocatechin-3-gallate against ovarian carcinoma cell lines. Cancer Res Treat. 2004;36(5):315–323. doi:10.4143/crt.2004.36.5.31520368822
   PubMedGoogle Scholar
• SpinellaF, RosanòL, DecandiaS, et al. Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med (Maywood). 2006;231(6):1123–1127.16741061
   PubMed Web of Science ®Google Scholar
• RavindranathMH, SaravananTS, MonteclaroCC, et al. Epicatechins purified from green tea (camellia sinensis) differentially suppress growth of gender-dependent human cancer cell lines. Evid Based Complement Alternat Med. 2006;3(2):237–247. doi:10.1093/ecam/nel00316786054
   PubMed Web of Science ®Google Scholar
• SpinellaF, RosanòL, Di CastroV, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther. 2006;5(6):1483–1492. doi:10.1158/1535-7163.MCT-06-005316818507
   PubMed Web of Science ®Google Scholar
• YinZ, HenryEC, GasiewiczTA. (−)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor†. Biochemistry. 2009;48(2):336–345. doi:10.1021/bi801637q19113837
   PubMed Web of Science ®Google Scholar
• RaoSD, PagidasK. Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells. Anticancer Res. 2010;30(7):2519–2523.20682977
   PubMed Web of Science ®Google Scholar
• YanC, YangJ, ShenL, et al. Inhibitory effect of Epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression. Arch Gynecol Obstet. 2012;285(2):459–467. doi:10.1007/s00404-011-1942-621698451
   PubMed Web of Science ®Google Scholar
• WangF, ChangZ, FanQ, et al. Epigallocatechin‑3‑gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase‑2. Mol Med Rep. 2014;9(3):1085–1089. doi:10.3892/mmr.2014.190924452912
   PubMed Web of Science ®Google Scholar
• HarpoleJL, TucciM, BenghuzziH. Pathophysiological effects of thymoquinone and Epigallocatechin-3-gallate on SK-OV-3 ovarian cancer like cell line. Biomed Sci Instrum. 2015;51:31–39.25996696
   PubMedGoogle Scholar
• XinqiangS, MuZ, LeiC, MunLY. Bioinformatics analysis on molecular mechanism of green tea compound Epigallocatechin-3-gallate against ovarian cancer. Clin Transl Sci. 2017;10(4):302–307. doi:10.1111/cts.1247028504421
   PubMed Web of Science ®Google Scholar
• WangJ, ZhuC, SongD, et al. Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity. Cell Death Discov. 2017;3(1):17034. doi:10.1038/cddiscovery.2017.3428698806
   PubMed Web of Science ®Google Scholar
• ChanMM, SopranoK, WeinsteinK, et al. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol. 2006;207(2):389–396. doi:10.1002/jcp.2056916402374
   PubMed Web of Science ®Google Scholar
• YunosNM, BealeP, YuJQ, et al. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res. 2011;31(4):1131–1140.21508356
   PubMed Web of Science ®Google Scholar
• YunosNM, BealeP, YuJQ, et al. Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines. Anticancer Res. 2011;31(12):4283–4289.22199293
   PubMed Web of Science ®Google Scholar
• MazumderME, BealeP, ChanC, et al. Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells. Anticancer Res. 2012;32(11):4851–4860.23155251
   PubMed Web of Science ®Google Scholar
• ChenH, LandenCN, LiY, et al. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp Cell Res. 2013;319(5):697–706. doi:10.1016/j.yexcr.2012.12.02623333498
   PubMed Web of Science ®Google Scholar
• ChenH, LandenCN, LiY, et al. Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol. 2013;2013:872957. doi:10.1155/2013/87295723476648
   PubMedGoogle Scholar
• WangX, JiangP, WangP, et al. EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. PLoS One. 2015;10(4):e0125402. doi:10.1371/journal.pone.012540225927922
   PubMed Web of Science ®Google Scholar
• FabbriR, MaccioccaM, VicentiR, et al. Epigallocatechin-3-gallate inhibits doxorubicin-induced inflammation on human ovarian tissue. Biosci Rep. 2019;39(5):BSR20181424. doi:10.1042/BSR2018142430996116
   PubMed Web of Science ®Google Scholar
• BoussiosS, KarathanasiA, CookeD, et al. PARP inhibitors in ovarian cancer: the route to “Ithaca”. Diagnostics (Basel). 2019;9(2):55. doi:10.3390/diagnostics9020055
   PubMedGoogle Scholar